Lannett Company, Inc. (NYSE:LCI) entered into three-year agreement with Elite Pharmaceuticals
Lannett Company, Inc. (NYSE:LCI) announced that it has entered into a three-year agreement with Elite Pharmaceuticals to be the exclusive U.S. distributor of a Dantrolene Capsules 25 mg, 50 mg and 100 mg. Total U.S. sales of Dantrolene Capsules 25 mg, 50 mg and 100 mg was approximately $6.4 million for the 12 months ended April 2019, according to IQVIA, although actual generic market values are expected to be lower.
The stock Earnings per share (EPS) and the diluted EPS are the profitability measures used in the fundamental analysis of companies. The figure of EPS only takes into account a Lannett Company, Inc. (NYSE:LCI) common shares, whereas the very important diluted EPS take into account all the convertible securities such as convertible bonds/convertible preferred stock, which are changed into equity or common stock. Dilutive effects occur when the number of shares increases, for example, through a new issue. If a company issues more shares to shareholders and other investors, this increases the number of shares outstanding and decreases the company’s earnings per share. Ultimately, this can decrease the stock price.Lannett Company, Inc. (NYSE:LCI) Diluted EPS is -7.31, whereas the EPS Estimate for next year is 0.90. The Annual EPS Growth of past 5 years is 16.20% and Lannett Company, Inc. (NYSE:LCI) yearly performance is -54.44% and net profit margin is -39.80%.
Key Performance indicators for Lannett Company, Inc. (NYSE:LCI), in last 4 months the performance of LCI was -23.00% while its price to sale ratio is 0.35 and price to book ratio is 0.68. Company gross margin stands at 37.70% whereas its return on investment (ROI) is 8.10%.
On 28 June 2019, Lannett Company, Inc. (NYSE:LCI), a Healthcare sector firm, traded 1.41 Million shares in last trading session and stock fell -0.49% with closing price of $6.06 per share. with Lannett Company, Inc. (NYSE:LCI) traded 1.41 Million shares. The LCI distance from 20 day simple moving average is 7.97% and distance from 50-Day simple moving average is -3.65%.The relative strength index for stock is 52.24 and Average true range of LCI is 0.33.
Analyst’s mean target price for LCI is $8.88 while analysts mean recommendation is 3.00. The Stock value has moved between $3.33 – 14.43 in last one year. LCI market capitalization is 239.49 with beta of 2.49. Company has 5.90% insider ownership.
Lannett Company, Inc. (NYSE:LCI) is under coverage by number of analysts. Stock has got OUTPERFORM rating from 0 of Thomson Reuters analysts, 5 given HOLD rating to the stock and 0 given UNDERPERFORM rating. Buy rating has been given by 0 analysts to the company stock.